Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
CellaVision AB paidkr0.0 Mil more to buy back shares than it received from issuing new shares.
It spentkr0.4 Mil paying down its debt.
It paidkr0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It receivedkr0.0 Mil from paying cash dividends to shareholders.
It receivedkr0.0 Mil on other financial activities.
In all, CellaVision ABspentkr0.4 Mil on financial activities for the
three
months ended in Mar. 2026.
CellaVision AB (CHIX:CEVIs) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
CellaVision AB's issuance of stock for the
three
months ended in Mar. 2026 was kr0.0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
CellaVision AB's repurchase of stock for the
three
months ended in Mar. 2026 was kr0.0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
CellaVision AB's net issuance of debt for the
three
months ended in Mar. 2026 was kr-0.4 Mil.
CellaVision AB spentkr0.4 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
CellaVision AB's net issuance of preferred for the
three
months ended in Mar. 2026 was kr0.0 Mil.
CellaVision AB paidkr0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
CellaVision AB's cash flow for dividends for the
three
months ended in Mar. 2026 was kr0.0 Mil.
CellaVision AB receivedkr0.0 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
CellaVision AB's other financing for the
three
months ended in Mar. 2026 was kr0.0 Mil.
CellaVision AB receivedkr0.0 Mil on other financial activities.
CellaVision AB Cash Flow from Financing Related Terms
CellaVision AB Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for CellaVision AB's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
CellaVision AB's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-75.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of kr-75.2 Mil mean?
CellaVision AB (CHIX:CEVIS) has a Cash Flow from Financing of kr-75.2 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CellaVision AB and its competitors.
Is CellaVision AB's Cash Flow from Financing too high?
CellaVision AB's current Cash Flow from Financing is kr-75.2 Mil. Overall, CellaVision AB has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's Cash Flow from Financing compare to ABT and SYK?
CellaVision AB's Cash Flow from Financing of kr-75.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Medical Devices & Instruments company?
A good Cash Flow from Financing depends on the Medical Devices & Instruments industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for CellaVision AB and its competitors. CellaVision AB's current Cash Flow from Financing is kr-75.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current Cash Flow from Financing of kr-75.2 Mil. The stock's GF Value™ is kr243.89, compared to a current price of kr160.20 — trading 34.3% below its estimated fair value. The current Cash Flow from Financing is kr-75.2 Mil. CellaVision AB's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current Cash Flow from Financing is kr-75.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of kr160.20 is trading 34.3% below its estimated GF Value™ of kr243.89.
Key valuation signals for CHIX:CEVIS:
Cash Flow from Financing: kr-75.2 Mil
GF Value™: kr243.89 vs. price of kr160.20 (34.3% below fair value)
No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
93GF Score
Get the complete analysis for CHIX:CEVIS
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CEVIS has been successfully added to your 
